Nile Pharmaceuticals results, Fiscal year 2024
Net profit, assets, equity and cash flow for Fiscal year 2024, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit-32.16 millionEGP · −127.0% vs the same period a year earlier
Total assets1.47 billionEGP · +41.9% vs the same period a year earlier
Shareholders' equity469 millionEGP · −2.0% vs the same period a year earlier
Operating cash flow264 millionEGP · +203.0% vs the same period a year earlier
In short
- Nile Pharmaceuticals's net profit for Fiscal year 2024 was about -32.16 million EGP, down −127.0% from 119 million EGP in Fiscal year 2023.
- Total assets at the end of Fiscal year 2024 were about 1.47 billion EGP, and shareholders' equity about 469 million EGP.
- Operating cash flow for Fiscal year 2024 was positive at 264 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2023Change
Net profit-32.16 million119 million−127.0%
Gross profit583 million595 million−2.1%
Total assets1.47 billion1.04 billion+41.9%
Total liabilities1 billion560 million+79.4%
Shareholders' equity469 million478 million−2.0%
Total liabilities and equity1.47 billion1.04 billion+41.9%
Operating cash flow264 million-256 million+203.0%
Investing cash flow-237 million-27.52 million−762.9%
Financing cash flow34.63 million273 million−87.3%
Net change in cash148 million-11.38 million+1399.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy